



IPO NOTE

MOLBIO DIAGNOSTICS LIMITED



Rating:

SUBSCRIBE



ISSUE OFFER

Issue Opens on	AUG 10, 2026
Issue Close on	AUG 12, 2026
Total IPO size (cr)	₹940
Fresh issue (cr)	₹200
Offer For Sale (cr)	₹740
Price Band (INR)	₹768-807
Market Lot	18 SHARES
Face Value (INR)	₹1
Listing At	BSE, NSE
Market Cap (Pre IPO)	₹9,299.87 CR.

ISSUE BREAK-UP (%)

QIB Portion	50%
NII Portion	15%
Retail Portion	35%

INDICATIVE TIMETABLE

Basis of Allotment	13-08-2026
Refunds/Unblocking ASBA Fund	14-08-2026
Credit of Share to Demat A/c	14-08-2026
Listing Date	17-08-2026

Molbio Diagnostics Limited is a global point-of-care (POC) molecular diagnostics company engaged in the research, development, manufacturing, and commercialization of rapid diagnostic solutions for infectious and non-communicable diseases.


OBJECTS OF THE ISSUE

- Capital expenditure for R&D facilities and Centre of Excellence.
- Investment in plant & machinery for Goa and Visakhapatnam facilities.
- General Corporate Purposes

FINANCIALS (RESTATED CONSOLIDATED)

PARTICULARS (IN CRORE)	FY 2026	FY 2025	FY 2024
Equity Share Capital	11.2	22.5	22.5
Net Worth	1,144.68	952.95	807.94
Revenue from operations	1445.6	1020.4	836.5
EBITDA Margin%	22.56%	24.97%	22.02%
Net Profit/Loss of the year	164.14	138.58	83.54

FINANCIAL RATIOS OF FY26



OUTLOOK & VALUATION

- Valuations are in line with the industry average, priced below the listed peer average P/E of 64.9x.
- ₹200 crore fresh issue will fund capacity expansion at the Goa and Visakhapatnam facilities.
- Despite a sizeable OFS, the fresh proceeds are directed toward growth-oriented capital expenditure rather than debt reduction.
- Strong leadership in the molecular diagnostics segment, supported by a scalable device-and-consumables business model.
- Favorable long-term outlook, backed by healthy return ratios, margin expansion, and structural industry growth.



COMPANY PROFILE

- The company operates in the point-of-care diagnostics segment, focusing on rapid, accurate and cost-effective testing solutions.
- Its core offering is the proprietary Truenat platform, a portable and battery-operated molecular diagnostic system used for detecting infectious and select non-communicable diseases.
- The platform supports testing for multiple diseases, including tuberculosis, COVID-19, hepatitis, HIV and HPV.
- Molbio designs, manufactures and sells diagnostic devices, test kits and related consumables, supported by in-house research and development and multiple manufacturing facilities in India.
- Its products are supplied to government health programs, international aid agencies, hospitals and diagnostic laboratories in India and overseas.
- Its key strengths include indigenous technology, a diversified test menu, global regulatory acceptability and strong presence in public healthcare systems.



COMPETITIVE STRATEGIES

- Expand geographical presence in India and across the globe
- Continue to expand suite of diagnostic solutions for multiple diseases
- Develop new POC platforms for other communicable and non-communicable diseases
- Grow through strategic acquisitions and alliances and establish a centre of excellence



KEY CONCERNS

- Heavy dependence on government and international aid agency funding.
- High revenue concentration from tuberculosis-related test kits.
- A limited number of large customers contribute a significant share of revenues.
- Regulatory delays may impact the commercialisation of new diagnostic tests.
- Demand fluctuations are linked to public health policies and funding cycles.



KEY STRENGTHS

- Proprietary TruNAT platform enables rapid, point-of-care molecular diagnostics.
- Strong footprint in government and public health procurement programs.
- Wide disease coverage including TB, COVID-19, HIV, hepatitis and HPV.
- In-house R&D supported by integrated manufacturing capabilities.
- Global presence with products deployed across multiple countries.

COMPARISON WITH LISTED INDUSTRY PEERS

Name of the Company	EPS (₹ Basic)	P/E	NAV	Revenue (cr.)	RoNW%
Molbio Diagnostics Ltd.	14.77	55.43	101.51	1445.6	14.55
Peer Group					
Poly Medicure Ltd	31.79	52.61	306.45	1875.2	10.37
Dr. Lal Pathlabs Ltd	30.24	62.20	145.00	2762.9	20.78
Metropolis Healthcare Ltd	9.19	63.72	72.98	1645.8	12.56
Vijaya Diagnostic Centre Ltd	16.81	81.02	93.02	8142.0	18.07



DISCLAIMER:

The information contained herein are strictly confidential and are meant solely for the information of the recipient and shall not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written permission of Swastika Investmart Ltd. ("SIL"). The contents of this document are for information purpose only. This document is not an investment advice and must not alone be taken as the basis for an investment decision. Before taking any decision to invest, the recipient of this document must read carefully the Red Herring Prospectus ("RHP") issued to know the details of IPO and various risks and uncertainties associated with the investment in the IPO of the Company. All recipients of this document must before acting on the given information/details, make their own investigation and apply independent judgment based on their specific investment objectives and financial position. They can also seek appropriate professional advice from their own legal and tax consultants, advisors, etc. to understand the risks and investment considerations arising from such investment. The investor should possess appropriate resources to analyze such investment and the suitability of such investment to such investor's particular circumstances before making any decisions on the investment. The Investor shall be solely responsible for any action taken based on this document. SIL shall not be liable for any direct or indirect losses arising from the use of the information contained in this document and accept no responsibility for statements made otherwise issued or any other source of information received by the investor and the investor would be doing so at his/her/its own risk. The information contained in this document should not be construed as forecast or promise or guarantee or assurance of any kind. The investors are not being offered any assurance or guaranteed or fixed returns on their investments. The users of this document must bear in mind that past performances if any, are not indicative of future results. The actual returns on investment may be materially different than the past. Investments in Securities market products and instruments including in the IPO of the Company are highly risky and they are generally not an appropriate avenue for someone with limited resources/ limited investment and low risk tolerance. Such Investments are subject to market risks including, without limitation, price, volatility and liquidity and capital risks. Therefore, the users of this document must carefully consider all the information given in the RHP including the risks factors before making any investment in the Equity Shares of the Company.

Swastika Investmart Ltd or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither Swastika Investmart Ltd nor Research Analysts have any material conflict of interest at the time of publication of this report. Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Swastika Investment Ltd may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report. Research entity has not been engaged in market making activity for the subject company. Research analyst has not served as an officer, director or employee of the subject company. We have not received any compensation/benefits from the Subject Company or third party in connection with the Research Report.

CORPORATE & ADMINISTRATIVE OFFICE - 48, Jaora Compound, M.Y.H. Road, Indore - 452 001 | Phone 0731 - 6644000

Compliance Officer: Mrs. Dimple Soni Email: compliance@swastika.co.in Phone: (0731) 6644 241

Swastika Investmart Limited, SEBI Reg. No.: NSE/BSE/MSEI: INZ000192732 Merchant Banking: INM000012102 Investment Adviser: INA000009843 MCX/NCDEX: INZ000072532

Research Analyst Reg. No.: :INH000024073

CDSL/NSDL: IN-DP-115-2015 RBI Reg. No.: B-03-00174 IRDA Reg. No.: 713.

For additional information & risk factors please refer to the Red Herring Prospectus